Kev Dhaliwal

Kev Dhaliwal serves as the Chief Scientific Officer and Chief Medical Officer at Prothea Technologies, focusing on developing technologies to redefine patient care for lung disease. At the University of Edinburgh, Dhaliwal holds multiple influential positions, including Interim Director of the Edinburgh Futures Institute and Co-Director of the Baillie Gifford Pandemic Science Hub, where efforts involve genomic discovery and AI-driven innovation for pulmonary medicine. Dhaliwal also directs the Translational Healthcare Technologies Group and the Healthcare Technology Accelerator Facility, fostering interdisciplinary collaboration across several universities and the NHS. Additionally, Dhaliwal is a consultant in respiratory medicine at NHS Lothian and is a non-executive board member at CodeBase, enhancing the tech innovation ecosystem. Academic qualifications include a PhD in Inflammation and Imaging Technology and an MBBS, both from the University of Edinburgh, alongside a FRCP designation from the Royal College of Physicians London.